0001628908-25-000116
SEC filingRevenue fell 31% QoQ due to Performance Suite contract restructuring, but gross margin improved 610 bps to 22.6%.
For the three months ended June 30, 2025, total revenue decreased $202.8 million, or 31.3%, to $444.3 million compared to $647.1 million in the same period of 2024. The decline was primarily driven by contractual updates within the Performance Suite: $130.4 million from transitioning a customer to the Specialty Technology and Services Suite and $82.7 million from narrowing the scope of certain Performance Suite customers. Partial offsets included $16.0 million of growth in other contracts. Cost of revenue fell $196.4 million, or 36.3%, to $343.9 million, outpacing the revenue decline and resulting in gross margin improvement from 16.5% to 22.6%. Operating income swung from a profit of $7.8 million to a loss of $1.2 million, as selling, general and administrative expenses increased $6.0 million (8.7%) to $75.2 million, driven by higher personnel costs. Depreciation and amortization decreased $6.7 million to $23.1 million due to lower accelerated amortization on retired trade names. The change in fair value of contingent consideration resulted in a $3.2 million loss.
Performance Suite revenue fell sharply as average PMPM fees dropped from $22.30 to $13.76, while lives on platform decreased from 6.9 million to 6.5 million. This reflects the contractual restructuring that shifted a major customer to a lower-fee model. Specialty Technology and Services Suite saw average lives increase from 71.7 million to 77.0 million, with PMPM fees slightly down from $0.38 to $0.35, indicating volume growth offset by pricing pressure. Administrative Services remained relatively stable. Cases revenue increased slightly due to higher revenue per case ($2,969 vs. $2,849). By payer mix, Medicare revenue fell sharply (from $268.7M to $109.0M) due to the customer transitions, while Medicaid and Commercial revenue declined modestly.
Management noted that medical claims cost growth slowed in the first half of 2025 compared to 2024 but remained above historical averages, posing ongoing margin risk. The company is evaluating the impact of the newly enacted One Big Beautiful Bill Act (OBBBA) on tax expenses. The exchange of Series A Preferred Shares for second lien term loans on August 7, 2025, simplifies the capital structure. An incremental facility from Ares is available to retire the 2025 Notes and support working capital, with the company also considering alternative financing. No specific numerical guidance was provided, but management expects continued growth in the cost of treatment for cancer and cardiovascular patients, offset by contractual protections and clinical interventions.
As of June 30, 2025, Evolent Health held $151.0M cash and cash equivalents, with total debt of $820.6M (comprising $172.1M short-term and $648.5M long-term). Shareholders' equity stood at $896.0M. The company also had restricted cash of $26.975M. Total assets were $2.46B, including $1.14B goodwill and $651.2M intangible assets. The current ratio was 1.01 (current assets $562.3M vs current liabilities $557.5M). Note that the company's reserve for claims and performance-based arrangements declined sharply from $318.7M at year-end to $187.3M, reflecting higher claims payments and a change in mix.
Evolent has $15.0M in standby letters of credit and $16.5M in surety bonds. Operating lease obligations total $34.6M undiscounted, with a present value of $32.6M. The company has a Tax Receivables Agreement liability of $108.1M. No material purchase commitments for supplies or capacity were disclosed in the Notes.
Debt activity dominated the period: the company drew $200.0M from its Term Loan Facility in January 2025 and had $62.5M outstanding on its Revolving Facility as of June 30. Total debt increased by $158.6M from year-end. Capital expenditures were $17.4M, primarily for internal-use software development ($17.0M capitalized). Dividends on Series A Preferred Stock totaled $9.2M in cash. No common stock buybacks were reported.
The company operates as a single segment. Revenue is disaggregated by payer (Medicaid $381M, Medicare $224M, Commercial $322M for H1 2025) and by product suite (Performance Suite $571M, Specialty Technology $164M, Administrative Services $113M, Cases $80M). No further segment-level profitability is presented, as the CODM uses consolidated net loss as the primary performance measure.